Análisis de la acción Corvus Pharmaceuticals Inc (CRVS)CRVSCorvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corvus Pharmaceuticals Inc is a good buy right now due to its current price of $10.53, a year-to-date change of +43.85%, and a recent RSI of 58.681 suggesting bullish momentum. The insider purchase of 21,700 shares by David Scott Moore reflects strong confidence in the company, especially as the stock has surged 217% over the past year. However, the main risk is the negative earnings trend, with a projected EPS of -0.21 for the upcoming earnings report on November 3, 2026.

6 analysts cover CRVS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 13.33.